

Code	Indication	Status	Remarks
JR-141 BBB-penetrating iduronate-2-sulfatase (rDNA origin)	Hunter syndrome (LSD)	Phase III in Japan Phase II in Brazil	•ERT •J-Brain Cargo®
JR-162 J-Brain Cargo® -applied acid α-glucosidase (rDNA origin)	Pompe disease (LSD)	Preclinical	•ERT •J-Brain Cargo® •J-MIG System®
JR-171 BBB-penetrating α-L-iduronidase (rDNA origin)	Hurler syndrome (LSD)	Preclinical	•ERT •J-Brain Cargo® •J-MIG System®
JR-441 BBB-penetrating heparan N-sulfatase (rDNA origin)	Sanfilippo syndrome type A (LSD)	Preclinical	•ERT •J-Brain Cargo® •J-MIG System®
JR-131 Darbepoetin Alfa (rDNA origin)	Renal anemia	Filed	•Co-developed with Kissei Pharmaceutical Co., Ltd. •Biosimilar
JR-401X Somatropin (rDNA origin)	SHOX deficiency	Phase III	•Expanded Indication of GROWJECT®
JR-142 Long-acting human growth hormone (rDNA origin)	Growth disorders	Phase I	•J-MIG System®
JR-041 Follicle stimulating hormone (rDNA origin)	Infertility	Phase I/II	•Out-licensed to ASKA Pharmaceutical Co., Ltd.
JR-031 Mesenchymal stem cells	Epidermolysis bullosa	Filed	•Expanded Indication of TEMCELL® HS Inj. •Regenerative medical product
JR-031 Mesenchymal stem cells	Neonatal Hypoxic Ischemic Encephalopathy	Phase I/II in preparation	•Expanded Indication of TEMCELL® HS Inj. •Regenerative medical product
JTR-161/JR-161 Dental pulp stem cells	Acute cerebral infarction	Phase I/II	•Co-developed with Teijin Limited •Regenerative medical product